begin model
# References:
#  - De Boer RJ, Ribeiro RM, Perelson AS (2010) Current estimates for HIV-1 production imply rapid viral clearance in lymphoid tissue. {\it PLOS Comput Biol} {\bf 6}: e1000906.
#  - Hlavacek WS, Stilianakis NI, Notermans DW, Danner SA, Perelson AS (2000) Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. {\it Proc Natl Acad Sci USA} {\bf 97}: 10966--10971
#  - Zhao J, Cao Y, Jusko WJ (2015) Across-species scaling of monoclonal antibody pharmacokinetics using a minimal PBPK model. {\it Pharm Res} {\bf 32}: 3269--3281.
#  - Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, Gris{\'{e}} H, Ofek GA, Taylor KA, Roux KH (2006) Distribution and three-dimensional structure of AIDS virus envelope spikes. {\it Nature} {\bf 441}: 847--852.
begin parameters



########## Best-fit parameter values ###############################################
# L = 1.381
KaA0__FREE 1.3890329004737958
KxRT__FREE 0.5507373324045526
R1__FREE 13.220323124393257
R2__FREE 83.26400782034793
c__FREE 141.50930133824738
f__FREE 0.08751020482882284
fp__FREE 0.004155165394696127
fr__FREE 0.2540344624654385
hatNc_ref__FREE 0.721235656179251
hatRT_ref__FREE 1.4619329808955643
hata_ref__FREE 4.549354628615683
hatmu__FREE 0.10998777213364487
hatp__FREE 0.05724935137648713
kE__FREE 5.89076464573708
kfRT__FREE 0.5832073900628251
kmc__FREE 0.15235176927883373
kpc__FREE 70.3774134892914
rho__FREE 0.004665299835427112
####################################################################################
###########################################
########## ADJUSTABLE PARAMETERS ##########
###########################################
# composite parameters R0 and R0_prime
#  - We assume that R0<R0_prime.
#  - R0 must be greater than 1 for persistent viral infection.
#  - The definitions of R0 and R0_prime have the same form as the expression 
#    for the basic reproduction number of the standard viral dynamics (SVD) model.
Rr = min(R1__FREE,R2__FREE) # dimensionless
Ra = max(R1__FREE,R2__FREE) # dimensionless
# rate constant for death of (uninfected) target cells
#  - We assume that naive (n) and activated (a) target cells have the same lifetime.
#  - We convert from /month to /d
mu = (12/365.25)*hatmu__FREE # /d
mu_r = mu # /d
mu_a = mu # /d
# fraction determining the relative lifetimes of short- and long-lived productively infected cells
#  - 0<f<1
#  - We expect f<<1.
#  - The lifetime of a short-lived infected cell is f*100 percent of the lifetime of a long-lived infected cell.
f = f__FREE # dimensionless
# rate constant for death of short-lived productively infected cells
#  - The rate constant for death of long-lived productively infected cells is f*delta.
delta = 1 # delta__FREE # /d
#delta_s = delta # /d
#delta_l = f*delta # /d
# rate constant characterizing generation of virus by productively infected cells
#  - We assume that short-lived (s) and long-lived (l) productively infected cells generate virus at the same per capita rate.
#  - We convert from /s to /d
p = (24*60*60)*hatp__FREE # /d
pS = p # /d
pL = p # /d
#p_s = p # /d
#p_l = p # /d
# rate constant for clearance of free virus (in the interstitial fluid of lymphoid tissue)
c = c__FREE # /d
# rate constant for progression of exposed cells through stages of the eclipse phase of infection
#  - We take the eclipse phase to consist of three stages, each of equal expected duration.
kE = kE__FREE # /d
# ratio p_s*[Il()]:p_l*[Is()] in steady state of persistent viral infection
#  - We expect 0<rho<<1.
rho = rho__FREE # dimensionless
# fraction that determines the values of alpha and gamma
#  - 0<fp<1
fp = fp__FREE # dimensionless
# fraction that determines the value of r
#  - 0<fr<1
fr = fr__FREE # dimensionless
# initial number of target + non-target CD4+ cells for reference body weight
sumT_ref = 5.72e10 # population
# number of CD4- mononuclear cells at reference body weight
#  - We convert from number of billions to number
Nc_ref = 1e12*hatNc_ref__FREE # population
# composite body weight-independent parameter KaA0
#  - The affinity (Ka) of anti-CD21 for CR2/CD21 on FDCs and the free Ab concentration (A0) 
#    need not be known independently because we are assuming that A0 is unperturbed by Ab interaction 
#    with viral receptors on FDCs, as would be the case if the antibody is available in excess and/or its
#    concentration is buffered.
KaA0 = KaA0__FREE # dimensionless
# composite body weight-independent parameter KxRT
#  - This quantity is the single-site equilibrium crosslinking constant for virion-receptor interaction 
#    multiplied by the total receptor niumber.
KxRT = KxRT__FREE # dimensionless
# total number of receptors for reference body weight
#  - The quantity hatRT_ref is trillions of receptors.
RT_ref = hatRT_ref__FREE*1e12 # population
# total FDC surface area for reference body weight
#  - The quantity hata_ref has units m^2.
a_ref = hata_ref__FREE*1e6 # mm^2
# composite body weight-independent parameter kfRT 
#  - The quantity kf is the single-site rate constant for virion-receptor association.
#  - The quantity RT is the total receptor number.
kfRT = kfRT__FREE # /d
# rate constant for immobilization/trapping/isolation of virion-crosslinked receptor aggregates
kpc = kpc__FREE # /d
# rate constant for reversal of immobilization/trapping/isolation
kmc = kmc__FREE # /d
######################################################
########## FIXED AND CONSTRAINED PARAMETERS ##########
######################################################
# reference body weight
w_ref 8.07 # kg
# cohort-specific (arithmetic mean) body weight 
#  - phase 1 control animals: 5.32 kg 
#  - phase 1 treated animals: 5.24 kg
#  - phase 2 control animals: 7.67 kg
#  - phase 2 treated animals: 8.09 kg
w 5.32 # kg
# blood plasma volume for reference body weight
#  - See Table I in Zhao et al. (2015).
#  - According to Zhao et al. (20150, nuP = 0.157 L for a body weight of 3.5 kg.
#  - It follows that nuP = 0.362 L for a body weight of 8.07 kg.
nuP_ref 0.362 # L
# cohort-specific blood plasma volume
nuP = nuP_ref*(w/w_ref) # L
# ratio T0:(Tn+Ta), where Tn and Ta are evaluated at the steady state of persistent viral infection
#  - Recall that R0<R0_prime.
r = Rr+fr*(Ra-Rr) # dimensionless ratio
# ratio (CD4+ cells before infection):(CD4+ cells after infection)
#  - CD4_before_infection 5.78e10 # population
#  - CD4_after_infection 1.88e10 # population
r_prime = 3.07 # dimensionless ratio
# steady-state fraction of target cells that are naive (vs. activated)
theta = (Ra-r)/(Ra-Rr) # dimensionless
# cohort-specific initial number of target cells
T0 = (r*(r_prime-1))/(r_prime*(r-1))*sumT_ref*(w/w_ref) # population
# cohort-specific number of CD4+ cells invulnerable to infection
#  - This population includes CD4+ cells lacking a coreceptor, etc.
T0_prime = (r-r_prime)/(r_prime*(r-1))*sumT_ref*(w/w_ref) # population
# cohort-specific number of CD4- mononuclear cells
Nc = Nc_ref*(w/w_ref) # population
# rate of de novo generation of (naive) target cells
lmbda = mu_r*T0 # /d
# rate constant for import of virions (De Boer et al., 2010)
#  - virions move from lymphoid tissue to blood plasma
ki 2.4 # /d
# rate constant for export of virions (De Boer et al., 2010)
#  - virions move from blood plasma to interstitial fluid
ke 240 # /d
# fraction of virions returning to lymphoid tissue from blood plasma (De Boer et al., 2010) 
ft 0.5 # dimensionless
# fraction of exposed cells that become long-lived productively infected cells
#  - We expect eps<<1.
eps = rho*f/(rho*f+pL/pS) # dimensionless
# ratio
chi = (ki/c)*(1-ft) # dimensionless
# a quantity approximately equal to 1
Omega = (1+rho)*(1-eps)/(1+chi) # dimensionless
# rate constants for infection of resting (r) and activated (a) target cells
beta_r = c*delta*Rr/(pS*Omega*T0)
beta_a = c*delta*Ra/(pS*Omega*T0)
# rate constant for virus-dependent activation of naive cells
phi = fp*min(1,(mu_r/mu_a)*(r-theta)/(1-theta)) # dimensionless
alpha = phi*(beta_r+beta_a*(mu_r/mu_a)*(r/theta-1))/((mu_r/mu_a)*(r-theta)/(1-theta)-phi) # /d
# rate constant for virus-dependent proliferation of activated cells
gamma = (1-phi)*(beta_a+(mu_a/mu_r)*(alpha+beta_r)/(r/theta-1))
# geometric mean viral load for all Phase II animals (control and treated) at t = 6 weeks (42 d) p.i.
Gv 787504 # vRNA copies per mL
# virion valence
#  - The valence of a virion is related to the number of Env spikes per virion.
#  - HIV has 14 Env spikes per virion and SIVmac239 has 73 Env spikes per virion (Zhu et al., 2006).
n 14 # dimensionless
# cohort-specific total number of viral receptors on FDCs
RT = RT_ref*(w/w_ref) # population
# cohort-specific total FDC surface area
a = a_ref*(w/w_ref) # mm^2
# single-site virion-receptor dissociation rate constant 
#  - See Table 2 in Hlavacek et al. (2000). See references cited therein.
kr = 0.1*(60*60*24) # 0.1 /s converted to 8640 /d
# single-site virion-receptor association rate constant
kf = kfRT/RT # /d
# reverse crosslinking constant
kmx = kr # /d
# forward crosslinking constant
kpx = kmx*KxRT/RT # /d
# rate constant for anti-CD21 Ab-receptor dissociation 
kd = 0.01*(60*60*24) # 0.01 /s converted to 864 /d
# rate constant for Ab-receptor association
kaA0 = kd*KaA0 # /d
# anti-retroviral therapy (ART) indicator
ART 0 # 0 (-ART) or 1 (+ART)
# anti-CD21 antibody therapy (Ab) indicator
thera_Ab 0 # 0 (-Ab) or 1 (+Ab)
end parameters
begin molecule types
counter()
Tr() # resting target cells
Ta() # virus-activated target cells
E1() # pre-symptomatic exposed cells in stage 1 of eclipse phase 
E2() # pre-symptomatic exposed cells in stage 2 of eclipse phase
E3() # pre-symptomatic exposed cells in stage 3 of eclipse phase
IS() # short-lived productively infected cells
IL() # long-lived productively infected cells
V() # free virions in interstitial fluid surrounding follicular dendritic cells (FDCs)
VP() # free virions in blood plasma
R() # free viral receptors on FDCs
R01() # singly-bound FDC-associated virions / unaggregated bound viral receptors
R02() # doubly-bound FDC-associated virions / virion-crosslinked aggregates of two viral receptors
# virion-crosslinked aggregates of viral receptors (size 3 to 14)
#  - These aggregates can become transiently immobilized.
R03(mobile~T~F)
R04(mobile~T~F)
R05(mobile~T~F)
R06(mobile~T~F)
R07(mobile~T~F)
R08(mobile~T~F)
R09(mobile~T~F)
R10(mobile~T~F)
R11(mobile~T~F)
R12(mobile~T~F)
R13(mobile~T~F)
R14(mobile~T~F)
S() # sequestered receptors (bound to antibody)
end molecule types
begin seed species
counter() 0
Tr() T0
Ta() 0
E1() 0
E2() 0
E3() 0
IS() 1
IL() 0
V() 0
VP() 0
R() RT
# species not listed have initial abundance 0 (by default)
end seed species
begin observables
Molecules t counter()
Molecules Tr Tr()
Molecules Ta Ta()
Molecules E1 E1()
Molecules E2 E2()
Molecules E3 E3()
Molecules IS IS()
Molecules IL IL()
Molecules V V()
Molecules VP VP()
Molecules R R() 
Molecules B R01() R02() R03() R04() R05() R06() R07() R08() R09() R10() R11() R12() R13() R14() # population of FDC-associated virions
Molecules S S() 
end observables
begin functions
# sanity checks
report_Rr()=Rr
report_Ra()=Ra
# data and corresponding simulation outputs
#######################################
########## plasma viral load ##########
#######################################
# plasma viral load
#  - Note that 15 copies per mL is the limit of detection.
#  - [Vp()] is approximately (ki/ke)*[Vf()].
#  - Simulation outputs below the limit of detection are censored.
log_pVL()=if(VP>(15*1000/2)*nuP,log10(2*VP/(1000*nuP)),1.176) # log10(vRNA copies per mL)
#log_pVL_approx()=if(Vf>(15*1000/2)*(ke/ki)*nuP,log10(2*Vf*(ki/ke)/(nuP*1000)),1.176) # log10(vRNA copies per mL)
log_pVL_p1_C()=if(t< 7,1.176091259,\
if(t<14,5.872825680,\
if(t<21,7.271765428,\
if(t<28,6.652363064,\
if(t<35,6.537802956,\
if(t<42,6.199181106,\
if(t<49,5.880386327,\
if(t<56,5.920500486,\
if(t<60,6.083642508,0)))))))))
log_pVL_p1_T()=if(t< 7,1.176091259,\
if(t<14,5.843776587,\
if(t<21,7.549073893,\
if(t<28,6.704401913,\
if(t<35,6.458363513,\
if(t<42,6.102778765,\
if(t<49,5.382656780,\
if(t<56,5.821900523,\
if(t<60,5.781070187,0)))))))))
log_pVL_p2_C()=if(t< 7,1.176091259,\
if(t<14,5.712486031,\
if(t<21,7.153994248,\
if(t<28,6.354212256,\
if(t<35,6.161951654,\
if(t<42,5.692717962,\
if(t<43,5.914894404,\
if(t<45,5.687,\
if(t<49,4.874,\
if(t<56,3.992,\
if(t<63,3.237,\
if(t<70,3.297,\
if(t<77,3.148,\
if(t<84,2.807,\
if(t<88,2.402,0)))))))))))))))
log_pVL_p2_T()=if(t< 7,1.176091259,\
if(t<14,5.445937944,\
if(t<21,7.175144927,\
if(t<28,6.423994503,\
if(t<35,6.168238474,\
if(t<42,5.726241912,\
if(t<43,5.883825458,\
if(t<45,5.659,\
if(t<49,4.938,\
if(t<56,4.124,\
if(t<63,3.546,\
if(t<70,3.346,\
if(t<77,3.188,\
if(t<84,2.954,\
if(t<88,2.460,0)))))))))))))))
#################################################
########## frequency of infected cells ##########
#################################################
# frequency of infected cells
#  - NB: only the p1_C and p1_T counts at time t=56 d (8 weeks) p.i. were considered in model parameterization.
#  - Counts of infected cells seem to be very noisy.
log_freqI()=log10(1e5*(IS+IL)/(IS+IL+E1+E2+E3+Tr+Ta+T0_prime+Nc)) # log10(number of infected cells per 100,000 mononuclear cells)
# data for control animals log10(geomtric mean)
log_freqI_p1_C()=if(t<14, 0,\
if(t<28,2.156,\
if(t<56,2.089,\
if(t<60,1.951,0))))
# data for treated animals log10(geometric mean)
log_freqI_p1_T()=if(t<14, 0,\
if(t<28,2.263,\
if(t<56,2.062,\
if(t<60,1.592,0))))
####################################
########## FDC viral load ##########
####################################
# whole-body number of FDC-associated virions
#  - NB: the p2_C and p2_T readouts are body weight-adjusted values of the p1_C empirical estimate.
#  - Synthetic data derived from empirical estimates and body weight adjustments were used in initial model parameterization. See notes.
#  - Only the p1_C and p1_T empirical estimates at t=56 d (8 weeks) p.i. were used in final paramterization.
log_B()=if(B>0,log10(B),0) # log10(number of FDC-associated virions)
log_B_p1_C_ss_untreated()=10.91 # empirical estimate of FDC viral load at time t=56 d (8 weeks) p.i.
log_B_p1_T_ss_plusAb()=9.756 # empirical estimate of FDC viral load at time t=56 d (8 weeks) p.i.
log_B_p2_C_ss_beforeART()=11.07 # untreated
log_B_p2_T_ss_beforeART()=11.10 # untreated, = 9.944 (+Ab treatment at time of infection)
###############################################################
########## surface density of FDC-associated virions ##########
###############################################################
# surface density of FDC-associated virions
#  - Note that 1 virion per mm^2 is taken as the limit of detection.
#  - Simulation outputs below the limit of detection are censored.
log_dens()=if(B/a>1,log10(B/a),0) # virions per mm^2
log_dens_p2_C()=if(t<49,4.299,\
if(t<56,4.120,\
if(t<70,3.604,\
if(t<84,3.091,\
if(t<88,2.541,0)))))
log_dens_p2_T()=if(t<49,4.240,\
if(t<56,3.948,\
if(t<70,3.368,\
if(t<84,2.680,\
if(t<88,1.758,0)))))
# simulation outputs
# abundance of CD4+ cells
#  - By construction, the drop in CD4+ cell count is consistent with observation (characterized by r_prime).
Nt_CD4_cell_count()=T0_prime+Tr+Ta
# fraction of receptors bound to virions
fV_bnd_to_virion()=1-(R+S)/RT
# fraction of receptors bound to antibodies
#  - We expect a significant fraction of receptors to be occupied by antibody 
#    from assays of antibody binding to CR2/CD21 on B cells.
fA_bnd_to_Ab()=S/RT
# fraction of CD4+ cells invulnerable to infection
f_CD4pos_invulnerable()=T0_prime/(T0+T0_prime)
# [CD4+ cells] / [CD4- mononuclear cells + CD4+ cells]
f_monoCells_CD4pos()=(T0+T0_prime)/(T0+T0_prime+Nc)
# log-transformed geometric mean plasma viral load for phase 2 animals (control and treated) at time t=42 d p.i.
#log_Gv_phase2()=log10(Gv)
end functions
begin reaction rules
# timer
0->counter() 1
# de novo generation of naive target cells
0->Tr() lmbda
# virus-dependent activation of naive cells
Tr()+V()->Ta()+V() alpha
# virus-dependent proliferation of activated cells
Ta()+V()->Ta()+Ta()+V() gamma
# infection of target cells
Tr()+V()->E1()+V() beta_r*(1-ART)
Ta()+V()->E1()+V() beta_a*(1-ART)
# death of target cells
Tr()->0 mu_r
Ta()->0 mu_a
# progression through the eclipse phase of infection
#  - The vast majority of exposed cells become short-lived productively infected cells.
#  - A small fraction of exposed cells, eps, become long-lived productively infected cells.
E1()->E2() kE
E2()->E3() kE
E3()->IS() kE*(1-eps) 
E3()->IL() kE*eps
# death of infected cells
#  - Recall that 0<f<1.
IS()->0 delta
IL()->0 f*delta
# generation of virus by productively infected cells
IS()->IS()+V() pS
IL()->IL()+V() pL
# clearance of virus
V()->0 c
# transport of free virus between interstitial fluid of lymphoid tissue and blood plasma
V()<->VP() ki,ft*ke
# export of virus from blood plasma to sink (iterstitial fluid of non-lymphoid tissues/organs)
VP()->0 (1-ft)*ke
# capture/release of free virions by viral receptors on FDCs
V()+R()<->R01() n*kf,kr
# reversible crosslinking of viral receptors by FDC-tethered virions
R01()+R()<->R02() (n-1)*kpx,2*kmx
R02()+R()<->R03(mobile~T) (n-2)*kpx,3*kmx
R03(mobile~T)+R()<->R04(mobile~T) (n-3)*kpx,4*kmx
R04(mobile~T)+R()<->R05(mobile~T) (n-4)*kpx,5*kmx
R05(mobile~T)+R()<->R06(mobile~T) (n-5)*kpx,6*kmx
R06(mobile~T)+R()<->R07(mobile~T) (n-6)*kpx,7*kmx
R07(mobile~T)+R()<->R08(mobile~T) (n-7)*kpx,8*kmx
R08(mobile~T)+R()<->R09(mobile~T) (n-8)*kpx,9*kmx
R09(mobile~T)+R()<->R10(mobile~T) (n-9)*kpx,10*kmx
R10(mobile~T)+R()<->R11(mobile~T) (n-10)*kpx,11*kmx
R11(mobile~T)+R()<->R12(mobile~T) (n-11)*kpx,12*kmx
R12(mobile~T)+R()<->R13(mobile~T) (n-12)*kpx,13*kmx
R13(mobile~T)+R()<->R14(mobile~T) (n-13)*kpx,14*kmx
# temporary confinement of virion-crosslinked receptor aggregates containing three or more receptors
R03(mobile~T)<->R03(mobile~F) kpc,kmc
R04(mobile~T)<->R04(mobile~F) kpc,kmc
R05(mobile~T)<->R05(mobile~F) kpc,kmc
R06(mobile~T)<->R06(mobile~F) kpc,kmc
R07(mobile~T)<->R07(mobile~F) kpc,kmc
R08(mobile~T)<->R08(mobile~F) kpc,kmc
R09(mobile~T)<->R09(mobile~F) kpc,kmc
R10(mobile~T)<->R10(mobile~F) kpc,kmc
R11(mobile~T)<->R11(mobile~F) kpc,kmc
R12(mobile~T)<->R12(mobile~F) kpc,kmc
R13(mobile~T)<->R13(mobile~F) kpc,kmc
R14(mobile~T)<->R14(mobile~F) kpc,kmc
# sequestration of viral receptors on FDCs through binding to therapeutic antibody
R()<->S() thera_Ab*kaA0,kd
end reaction rules
end model
begin actions
generate_network({overwrite=>1})
saveConcentrations()
###########################################
##### Phase I data - control animals ######
###########################################
resetConcentrations()
# simulate untreated infection
setParameter("w",5.32) # arithmetic mean body weight (kg) of Phase I control animals
setParameter("ART",0) # -ART, no antiretroviral therapy
setParameter("thera_Ab",0) # -Ab, no antibody treatment
simulate({suffix=>"p1_control",method=>"ode",t_start=>0,t_end=>56,n_steps=>560,print_functions=>1})
###########################################
##### Phase I data - treated animals ######
###########################################
resetConcentrations()
# simulate infection + Ab
setParameter("w",5.24) # arithmetic mean body weight (kg) of Phase I treated animals
setParameter("ART",0) # -ART, no antiretroviral therapy
setParameter("thera_Ab",1) # +Ab, antibody treatment
simulate({suffix=>"p1_treated",method=>"ode",t_start=>0,t_end=>56,n_steps=>560,print_functions=>1})
###########################################
##### Phase II data - control animals #####
###########################################
resetConcentrations()
# simulate untreated infection
setParameter("w",7.67) # arithmetic mean body weight (kg) of Phase II control animals
setParameter("ART",0) # -ART, no antiretroviral therapy
setParameter("thera_Ab",0) # -Ab, no antibody treatment
simulate({suffix=>"p2_control",method=>"ode",t_start=>0,t_end=>42,n_steps=>420,print_functions=>1})
# simulate ART
setParameter("ART",1) # +ART
simulate({suffix=>"p2_control",continue=>1,method=>"ode",t_start=>42,t_end=>88,n_steps=>460,print_functions=>1})
###########################################
##### Phase II data - treated animals #####
###########################################
resetConcentrations()
setParameter("w",8.09) # arithmetic mean body weight (kg) of Phase II treated animals
setParameter("ART",0) # -ART, no antiretroviral therapy
setParameter("thera_Ab",0) # -Ab, no antibody treatment
# simulate untreated infection
simulate({suffix=>"p2_treated",method=>"ode",t_start=>0,t_end=>42,n_steps=>420,print_functions=>1})
# simulate ART
setParameter("ART",1) # +ART
simulate({suffix=>"p2_treated",continue=>1,method=>"ode",t_start=>42,t_end=>49,n_steps=>70,print_functions=>1})
# simulate treatment with therapeutic antibody
setParameter("thera_Ab",1) # +Ab
simulate({suffix=>"p2_treated",continue=>1,method=>"ode",t_start=>49,t_end=>88,n_steps=>390,print_functions=>1})
end actions